Edetate calcium disodium anhydrous API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Edetate calcium disodium anhydrous API 62-33-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Edetate calcium disodium anhydrous. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Edetate calcium disodium anhydrous
- Synonyms:
- Edetate calcium disodium (anhydrous) , Edetic acid calcium disodium salt
- Cas Number:
- 62-33-9
- DrugBank number:
- DB14598
- Unique Ingredient Identifier:
- 8U5D034955
General Description:
Edetate calcium disodium anhydrous, identified by CAS number 62-33-9, is a notable compound with significant therapeutic applications. Edetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body. It is on the World Health Organization Model List of Essential Medicines. Edetate calcium disodium was granted FDA approval on 16 July 1953.
Indications:
This drug is primarily indicated for: Edetate calcium disodium is indicated to reduce blood levels and depot stores of lead in acute and chronic lead poisoning. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Edetate calcium disodium anhydrous undergoes metabolic processing primarily in: Edetate calcium disodium is almost completely unmetabolized _in vivo_. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Edetate calcium disodium anhydrous are crucial for its therapeutic efficacy: Calcium edetate disodium's Cmax and AUC are dependant on renal function. 5% of an oral dose is absorbed from the gastrointestinal tract. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Edetate calcium disodium anhydrous is an important consideration for its dosing schedule: The half life of edetate calcium disodium is 20-60 minutes. This determines the duration of action and helps in formulating effective dosing regimens.
Route of Elimination:
The elimination of Edetate calcium disodium anhydrous from the body primarily occurs through: Edetate calcium disodium is 95% eliminated in the urine within 24 hours. An oral dose in rats was 88.32% recovered in the feces and 10.30% recovered in the urine. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Edetate calcium disodium anhydrous is distributed throughout the body with a volume of distribution of: The volume of distribution of edetate calcium disodium is 0.19±0.10L/kg. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Edetate calcium disodium anhydrous is a critical factor in determining its safe and effective dosage: The mean clearance of edetate in 1 month olds is 54.6mL/min/1.73m2. 2-17 year olds have a mean clearance of 113.9±24.4mL/min/1.73m2. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Edetate calcium disodium anhydrous exerts its therapeutic effects through: Edetate calcium disodium is a polyvalent ion chelator used to remove lead from the body after lead poisoning. It has a wide therapeutic index, as overdoses must be well in excess of the therapeutic dose to show symptoms. It has a long duration of action, as doses are given at least a day apart. Patients should be counselled regarding the risk of increased intracranial pressure with intravenous infusions. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Edetate calcium disodium anhydrous functions by: Edetate calcium disodium distributes into tissues, such as the kidney and bone, where it chelates lead ions. The lead ions are then eliminated in the normal urinary excretion of edetate. Lead in certain tissues such as the liver and bone, redistribute to other tissues after edetate calcium disodium treatment, but lead levels do not decrease to levels seen in unexposed patients. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Edetate calcium disodium anhydrous belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups, classified under the direct parent group Tetracarboxylic acids and derivatives. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Carboxylic acids and derivatives class, specifically within the Tetracarboxylic acids and derivatives subclass.
Categories:
Edetate calcium disodium anhydrous is categorized under the following therapeutic classes: Acetates, Acids, Acyclic, Amines, Anticoagulants, Calcium Chelating Activity, Calcium Chelating Agents, Chelating Activity, Chelating Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Diamines, Diet, Food, and Nutrition, Ethylenediamines, Food, Food Additives, Food Ingredients, Hematologic Agents, Iron Chelating Activity, Iron Chelating Agents, Lead Chelating Activity, Lead Chelator, Metal Chelating Activity, Metal Chelator, Physiological Phenomena, Polyamines, Sequestering Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Edetate calcium disodium anhydrous include:
- Melting Point: >300
Edetate calcium disodium anhydrous is a type of Enzyme Replacements/modifiers
Enzyme replacements/modifiers are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various enzyme-related disorders. Enzymes play a vital role in the normal functioning of the body by catalyzing specific biochemical reactions. However, in certain medical conditions, the body may lack or produce dysfunctional enzymes, leading to serious health complications.
Enzyme replacement therapy (ERT) involves administering exogenous enzymes to compensate for the enzyme deficiency in patients. These enzymes are typically derived from natural sources or produced using recombinant DNA technology. By introducing these enzymes into the body, they can effectively substitute the missing or defective enzymes, thereby restoring normal metabolic processes.
On the other hand, enzyme modifiers are API substances that regulate the activity of specific enzymes within the body. These modifiers can either enhance or inhibit the enzyme's function, depending on the therapeutic objective. By modulating enzyme activity, these APIs can restore the balance of enzymatic reactions, leading to improved physiological outcomes.
Enzyme replacements/modifiers have shown remarkable success in treating various genetic disorders, such as Gaucher disease, Fabry disease, and lysosomal storage disorders. Additionally, they have demonstrated potential in managing enzyme deficiencies associated with rare diseases and certain types of cancer.
The development and production of enzyme replacements/modifiers involve rigorous research, formulation optimization, and adherence to stringent quality control measures. Pharmaceutical companies invest substantial resources in developing these APIs to ensure their safety, efficacy, and compliance with regulatory standards.
Overall, enzyme replacements/modifiers represent a vital therapeutic category in modern medicine, offering hope and improved quality of life for patients with enzyme-related disorders.
